Emerging trends in tuberculosis therapy - A review

Journal of Scientific and Industrial Research

Volumn 66, Issue 3, 2007, Pages 191-208

  Agrawal, Yadvendra K ^a   Bhatt, Hardik G ^a   Raval, Hitesh G ^b   Oza, Pratik M ^b   Vaidya, Hitesh B ^a   Manna, Kuntal ^a   Gogoi, Parthajyoti ^a  

^a NIRMA UNIVERSITY   (India)

^b ANAND PHARMACY COLLEGE   (India)

Author keywords

Antimycobacterial agents; Cell envelope; Drugs; MIC; Mycobacterium tuberculosis; Targets; Therapeutic agents

Indexed keywords

ANTIGEN-ANTIBODY REACTIONS; BACTERIOPHAGES; CELLS; DRUG PRODUCTS; PULMONARY DISEASES;

DISEASE TREATMENT; DRUG; IMMUNE SYSTEM; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM TUBERCULOSIS;

EID: 33947214354     PISSN: 00224456     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (101)

1. Lemke T L, in Foye's Principles of Medicinal Chemistry by T L Lemke & D A Williams, 5th edn (Lippincott Williams & Wilkins, USA) 2002, 904-906.
2. Panchagnula R, Agrawal S & Kaul C L, Fixed dose combinations in treatment of tuberculosis, Indian J Pharm Sci, 63 (2001) 1-9.
3. www.who.org
4. Petri W A, in Goodman and Gilman's The Pharmacological Basis of Therapeutics by J G Hardman & L E Limbird, 11th edn (MaGraw Hill), 2006, 1203-1223.
5. Kuo M R, Morbidoni H R, Alland D, Sneddon S F, Gourlie B B, Staveski M M, Leonard M, Gregory J S, Janjigian A D, Lee C, Musser J M, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs W R, Sacchettini J C & Fidock D A, Targeting tuberculosis and malaria through inhibition of enoyl reductase, J Biol Chem, 278 (2003) 20851-20859.
6. Lee R, Monsey D, Weston A, Duncan K, Rithner C & McNeil M, Enzymatic synthesis of UDP-galactofuranose and an assay for UDP-galactopyranose mutase based on high-performance liquid chromatography, Anal Biochem, 242 (1996) 1-7.
7. Lee R E, Brennan P J &Besra G S, Mycobacterial arabinan biosynthesis: The use of synthetic arabinoside acceptors in the development of an arabinosyl transfer assay, Glycobiology, 7 (1997) 1121-1128.
8. Ma Y, Mills J A, Belisle J T, Vissa V, Howell M, Bowlin K, Scherman M S & McNeil M, Determination of the pathway for rhamnose biosynthesis in mycobacteria: Cloning, sequencing and expression of the Mycobacterium tuberculosis gene encoding alpha-D-glucose-1-phosphate thymidylyltransferase, Microbiology, 143 (1997) 937-945.
9. Nassau P M, Martin S L, Brown R E, Weston A, Honsey D, McNeil M R & Duncan K, Galactofuranose biosynthesis in Escherichia coli K-12: Identification and cloning of UDP-galactopyranose mutase, J Bacteriol, 178 (1996) 1047-1052.
10. Takayama K, Wang C & Besra G S, Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis, Clin Microbiol Rev, 18 (2005) 81-101.
11. http://www.chemsoc.org/chembytes/ezine/1998/evans.htm
12. Sensi P & Grassi C G, in Berger's Medicinal Chemistry and Drug Discovery by M E Wolff, 5th edn (John-Wiley and sons Inc., USA) 1996, 576-635.
13. Beale J M, in Wilson and Giswold's Textbook of Organic Medicinal Chemistry by J M Beale & J H Block, 9th edn (Lippincott Williams & Wilkins, USA) 2004, 535-580.
14. Zeind C S, Gourley G K & Chandler-Toufieli D M, in Textbook of Therapeutics, Drug and Disease Management, by E T Harfindal & D R Gourley, 7th edn (Lippincott Williams & Wilkins, USA) 2004, 1427-1450.
15. Vohra R, Gupta M, Chaturvedi R & Singh Y, Attack on the scourge of tuberculosis: patented drug targets, Recent Patents on Anti-Infective Drug Discovery, 1 (2006) 95-106.
16. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P & Grosset J, In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis, Antimicrob Ag Chemother, 42 (1998) 2066-2069.
17. Miyazaki E, Miyazaki M, Chen J M, Chaisson R E & Bishai W R, Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone is active in a mouse model of tuberculosis, Antimicrob Ag Chemother, 43 (1999) 85-89.
18. Sullivan J T, Woodruff M, Lettieri J, Agarwal V, Krol G J, Leese P T, Watson S & Heller A H, Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone, Antimicrob Ag Chemother, 43 (1999) 2793-2797.
19. Biedenbach D J, Sutton L D & Jones R N, Antimicrobial activity of CS-940, a new trifluorinated quinolone, Antimicrob Ag Chemother, 39 (1995) 2325-2330.
20. Zhao B Y, Pine R, Domagala J & Drlica K, Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C-8 methoxyl Group on survival in liquid media and in human macrophages, Antimicrob Ag Chemother, 43 (1999) 661-666.
21. Onodera Y, Uchida Y, Tanaka M & Sato K, Dual inhibitory activity of sitafloxacin(DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae, J Antimicrob Chemother, 44 (1999) 533-536.
22. Roy B N, Karnik M A & Sankaran R, Recent advances in research on antituberculars, J Ind Chem Soc, 79 (2002) 320-335.
23. Sheu J Y, Chen Y L, Tzeng C C, Hsu S L, Fang K C & Wang T C, Synthesis, and antimycobacterial and cytotoxic evaluation of certain fluoroquinolone derivatives, Helv Chem Acta(Eng), 86 (2003) 2481-2489; Chem Abstr, 140 (2004) 16634.
24. Kunin C M & Ellis W Y, Antimicrobial activities of mefloquine and a series of related compounds, Antimicrob Ag Chemother, 44 (2000) 848-852.
25. Inderlied C B, Bermudez L, Ellis W Y, Aralar P A, Kolonoski P & Petrofsky M, Poster 999, presented at the 40th Interscience Conf on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 17 - 20 September, 2000,. Derwent World Drug Alert abstract WD-2000-013271.
26. Chambhare R V, Bobade A S & Khasde B G, Synthesis of novel 3-N-[(substitutedaryl/heterotryl)methylene]- imino-2-methyl-5-thienyl-thieno[2,3-d]pyrimidine4-(3H)-ones as possible antimicrobial agents, Ind J Het Chem, 12 (2002) 67-68.
27. Sriram D, Yogeeswari P, Pandeya S N & Ananthan S, Synthesis and antituberculous activity of n-mannich bases of 3-[4-(4-chlorophenyl)-6-(4-methylphenyl)pyrimidin-2-yl]iminoisatin derivatives, Scientia Pharmaceutica (Eng), 70 (2002) 39-48; Chem Abstr, 138 (2003) 89754.
28. Vanheusden V, Munier-Lehmann H, Busson R, Froeyen M, Dugue L, Heyerick A, Keukeleire D D, Pochet S, Busson R, Herdiwijn P & Calenbergh S V, 3′-C-Branched-chain-substituted nucleosides and nucleotides as potent inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase, J Med Chem, 46 (2003) 3811-3821.
29. Pathak A K, Pathak V, Seitz L E, Reynolds R C & Suling W J, Anti-mycobacterial agents: 1-Thio analogues of purine, J Med Chem, 47 (2004) 273-276.
30. Baker W R, Mitscher L A, Arain M A, Shaver R & Stover C K, Tuberculosis: A search for novel therapy starting with natural products, Annu Rep Med Chem, 31 (1996) 161-170.
31. Baker W R, Shaopei C & Keeler E L, US Pat 6, 087, 358 (2000); Chem Abstrt, 133 (2000) 89525.
32. Stover C K, Warrener P, VanDevanter D R, Sherman D R, Arain T M, Langhorne M H, Anderson S W, Towell J A, Yuan Y, McMurray D N, Kreiswirth B N, Barry C E & Baker W R, A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis, Nature, 405 (2000) 962-966.
33. Ashtekar D R, Rabi C P, Nagrajan K, Vishvanathan N, Bhatt A D & Rittel W, In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis, Antimicrob Ag Chemother, 37 (1993) 183-186.
34. Ma Y, Stern R J, Scherman M S, Vissa V D, Yan W, Jones V C, Zhang F, Franzblau S G, Lewis W H & McNeil M R, Drug targeting Mycobacterium tuberculosis cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose, Antimicrob Ag Chemother, 5 (2001) 1407-1416.
35. Andres C J, Bronson J J, D'Andrea S V, Deshpande M S, Falk P J, Grant-Young K A, Harte W E, Ho H T, Misco P F, Robertson J G, Stock D, Sun Y & Walsh A W, 4-Thiazolidinones: Novel inhibitors of the bacterial enzyme MurB, Bioorg Med Chem Lett, 10 (2000) 715-717.
36. Jones P B, Parrish N M, Houston T A, Stapon A, Bansal N P, Dick J D & Townsend C A, A new class of anti-tuberculosis agents, J Med Chem, 43 (2000) 3304-3314.
37. Kremer L, Maughan W N, Wilson R A, Dover L G & Besra G S, The M. tuberculosis antigen 85 complex and mycolyltransferase activity, Lett Appl Microbiol, 34 (2002) 233-237.
38. Rose J D, Maddry J A, Comber R N, Suling W J, Wilson L N & Reynolds R C, Synthesis and biological evaluation of trehalose analogs as potential inhibitors of mycobacterial cell wall biosynthesis, Carbohydr Res, 337 (2002) 105-120.
39. Wolucka B A, McNeil M R, deHoffman E, Chojnaki T & Brennan P J, Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria, J Biol Chem, 269 (1994) 23328-23335.
40. Scherman M S, Kalbe-Bournonville L, Bush D, Xin Y, Deng L & McNeil M, Polyprenylphosphate-pentoses in mycobacteria are synthesized from 5-phosphoribose pyrophosphate, J Biol Chem, 271 (1996) 29652-29658.
41. Centrone C A & Lowary T L, Synthesis and antituberculosis activity of C-phosphonate analogues of decaprenolphosphoarabinose, a key intermediate in the biosynthesis of mycobactedal arabinogalactan and lipoarabinomannan. J Org Chem, 67 (2002) 8862-8870.
42. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um K S, Wilson T, Collins D, de Lisle G & Jacobs W R Jr, InhA, a gene encoding a target for isoniazid and ethionamide in M. tuberculosis., Science, 263 (1994) 227-230.
43. Kuo M R, Morbidoni H R, Alland D, Sneddon S F, Gourlie B B, Staveski M M, Leonard M, Gregory J S, Janjigian A D, Lee C, Musser J M, Kreiswirth B, Iwamoto H, Perozzo R, Jacobs W R, Sacchettini J C & Fidock D A., Targeting tuberculosis and malaria through inhibition of enoyl reductase, J Biol Chem, 278 (2003) 20851-20859.
44. Temple C G, in Chemistry and Biology of Pteridines, by C Curius, S Ghisla & N Blau (Walter de Gruyter, Berlin, Germany) 1990, 1009-1014.
45. Temple C G, Wheeler G P, Elliott R D, Rose J D & Comber R N, Montgomery J A, 1,2-dihydropyrido[3,4-b]pyrazines: Structure-activity relationships, J Med Chem, 26 (1983) 91-95.
46. White E L, Suling W J, Ross L J, Seitz L E & Reynolds R C, 2-Alkoxycarbonylaminopyridines: Inhibitors of Mycobacterium tuberculosis FtsZ., J Antimicrob Chemother, 50 (2002) 111-114.
47. Suling W J, Seitz L E, Pathak V, Westbrook L, Barrow E W, Zywno-Van-Ginkel S, Reynolds R C, Piper J R & Barrow W W, Antimycobacterial activities of 2,4-diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase, Antimicrob Ag Chemother, 44 (2000) 2784-2793.
48. Tripathi R. P, Tripathi R, Tiwari V K, Bala L, Sinha S, Srivastava A, Srivastava R & Srivastava B S, Synthesis of glycosylated beta-amino acids as new class of antitubercular agents, Eur J Med Chem, 37 (2002) 773-781.
49. Yadav N, McDevitt R E, Benard S & Falco S C, Single amino acid substitutions in the enzyme acetolactate synthase confer resistance to the herbicide sulfometuron methyl, Proc Natl Acad Sci, 83 (1986) 4418-4422.
50. Andres C J, Bronson J J, D'Andrea S V, Deshpande M S, Falk P J, Grant-Young K A, Harte W E, Ho H T, Misco P F, Robertson J G, Stock D, Sun Y & Walsh A W, 4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB, Bioorg Med Chem Lett, 10 (2000) 715-717.
51. Velezheva V S, Brennan P J, Marshakov V Y, Gusev D V, Lisichkina I N, Pergudov A S, Tchernousova L N, Smirnova T G, Andreevskaya S N & Medvedev A E, Novel pyridazino[4,3-b]indoles with dual inhibitory activity against M. tuberculosis and monoamine oxidase, J Med Chem, 47 (2004) 3455-3461.
52. Andries K, A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis, Science, 307 (2005) 223-227.
53. Gundersen L, Nissen-Meyer J & Spilsberg B, Synthesis and antimycobacterial activity of 6-arylpurines: The requirements for the N-9 substituent in active anti-mycobacterial purines, J Med Chem, 45 (2002) 1383-1386.
54. Pathak A K, Pathak V, Seitz L E, Suling W J & Reynolds R C, Anti-mycobacterial agents: 1-Thio analogues of purine, J Med Chem, 47 (2004) 273-276.
55. Ballell L, Field R A, Duncan K & Young R J, New small-molecule synthetic antimycobacterials, Antimicrob Ag Chemother, 49 (2005) 2153-2163.
56. Deidda D, Lampis G, Fioravanti R, Biava M, Portea G, Zanetti S & Pompei R, Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains, Antimicrob Ag Chemother, 42 (1998) 3035-3037.
57. Biava M, BM 212 and its derivatives as a new class of anti-mycobacterial active agents, Curr Med Chem, 9 (1995) 1859-1869.
58. Scozzafava A, Mastrolenzo A & Supuran C T, Anti-mycobacterial activity of 9-sulfonylated/sulfenylated-6-mercaptopurine derivatives, Bioorg Med Chem Lett, 11 (2001) 1675-1678.
59. Pathak R, Shaw A K, Bhaduri A P, Chandrasekhar K V G, Sinha S, Srivastava A, Srivastava K K, Chaturvedi V, Srivastava R, Srivastava B S & Arora S, Higher acyclic nitrogen containing deoxy sugar derivatives: a new lead in the generation of antimycobacterial chemotherapeutics. Bioorg Med Chem, 10 (2002) 1695-1702.
60. Pathak R, Pant C S, Shaw A K, Bhaduri A P, Gaikwad A N, Sinha S, Srivastava A, Srivastava K K, Chaturvedi V, Srivastava R & Srivastava B S, Baylis-Hillman reaction: Convenient ascending syntheses and biological evaluation of acyclic deoxy monosaccharides as potential anti-mycobacterial agents, Bioorg Med Chem, 10 (2002) 3187-3196.
61. Dong Y, Matile H, Chollet J, Kaminsky R, Wood K & Vennerstrom J L, Synthesis and antimalarial activity of 11 dispiro-1,2,4,5-tetraoxane analogues of WR 148999. 7,8,15,16-tetraoxadispiro[5.2.5.2]hexadecanes substituted at the 1 and 10 positions with unsaturated and polar functional groups, J Med Chem, 42 (1999) 1477-1480.
62. Ghosal S, Biswas K & Chauduri R K, Chemical constituents of Gentianaceae. XXIV. Anti-Mycobacterium tuberculosis activity of naturally occurring xanthones and synthetic analogs, J Pharm Sci, 67 (1978) 721-722.
63. Savini L, Chiasserini L, Gaeta A & Pellerano C, Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones, Bioorg Med Chem, 10 (2002) 2193-2198.
64. Waisser K, Gregor J, Dostál H, Kubicová L, Klimeǒvá V & Kaustová J, Influence of the replacement of the oxo function with the thioxo group on the antimycobacterial activity of 3-aryl-6,8-dichloro-2H-1,3-benzoxazine-2,4(3H)-diones and 3-arylquinazoline-2,4(1H,3H)-diones, Farmaco. 56 (2001) 803-807.
65. Waisser K, Bures O, Holy P, Kunes J, Oswald R, Jiraskova L, Pour M, Klimesova V, Palat K, Kaustova J, Danse H M & Mollmann U, Antimycobacterial 3-aryl-2H-1,3-benzoxazine-2,4(3H)-diones, Pharmazie, 58 (2003) 83-94.
66. Ganley B, Chowdhury G, Bhansali J, Daniels J S & Gates K S, Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxide, Bioorg Med Chem, 9 (2001) 2395-2401.
67. Carta A, Loriga M, Paglietti G, Mattana A, Fiori P L, Mollicotti P, Sechi L & Zannetti S, Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides, Eur J Med Chem, 39 (2004) 195-203.
68. Ortega M A, Montoya M E, Jaso A, Zarranz B, Tirapu I, Aldana I & Monge A, Anti-mycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives, Pharmazie, 56 (2001) 205-207.
69. Zarranz B, Jaso A, Aldana I & Monge A, Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives, Bioorg Med Chem, 11 (2003) 2149-2156.
70. Waisser K, Klimesova V & Odlerová Z, Design of compounds active against Mycobacterium tuberculosis, Folia Pharm Univ Carol, 18 (1995) 31-37.
71. Gasparova R, Lacova M, El-Shaaer H M & Odlerová Z, Synthesis and antimycobacterial activity of some new 3-heterocyclic substituted chromones, Farmaco, 52 (1997) 251-253.
72. Vicini P, Geronikaki A, Incerti M, Busonera B, Poni G, Cabras C A & La Co!la P, Synthesis and biological evaluation of benzo[d]isothiazole, benzothiazole and thiazole Schiff bases, Bioorg Med Chem, 11 (2003) 4785-4789.
73. Savini L, Chiasserini L, Gaeta A & Pellerano C, Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones, Bioorg Med Chem, 10 (2002) 2193-2198.
74. Koketsu M, Tanaka K, Takenaka Y, Kwong C D & Ishihara H, Synthesis of 1,3-thiazine derivatives and their evaluation as potential antimycobacterial agents, Eur J Pharm Sci, 15 (2002) 307-310.
75. 2O, Heterocycles, 55 (2001) 1181-1188.
76. De Souza A O, Santos R R Jr, Ferreira-Julio J F, Rodríguez J A, Melo P S, Haun M, Sato D N & Durán N, Synthesis, antimycobacterial activities and cytotoxicity on V79 of 3-[4′-Y-(1,1′-biphenyl)-4-yl]-N,N-dimethyl-3-(4-X-phenyl)-2- propen-1-amine derivatives. Eur J Med Chem, 36 (2001) 843-850.
77. Klimesova V, Palat K, Waisser K & Klimes J, Combination of molecular modeling and quantitative structure-activity relationship analysis in the study of antimycobacterial activity of pyridine derivatives, Int J Pharm, 207 (2000) 1-6.
78. Agarwal N, Srivastava P, Raghuwanshi S K, Upadhyay D N, Sinha S, Shukla P K & Ram V J, Chloropyrimidines as a new class of antimicrobial agents, Bioorg Med Chem, 10 (2002) 869-874.
79. Biava M, Fioravanti R, Porretta G C, Sleiter G, Ettorre A, Deidda D, Lampis G & Pompei R, New toluidine derivatives with antimycobacterial and antifungal activities, Med Chem Res, (1997) 228-250.
80. Biava M, Fioravanti R, Porretta G C, Sleiter G, Ettorre A, Deidda D, Lampis G & Pompei R, Toluidine derivatives with antimycobacterial and antifungal activities, Med Chem Res, (1998) 523-533.
81. Suling W J & Maddry J A, Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro, J Antimicrob Chemother, 47 (2001) 451-454.
82. Diekema D J & Jones R N, Oxazolidinones, A review, Drugs, 59 (2000) 7-16.
83. Zurenko G E, Yagi B H, Schaadt R D, Allison J W, Kilburn J O, Glickman S E, Hutchinson D K, Barbachyn M R & Brickner S J, In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents, Antimicrob Ag Chemother, 40 (1996) 839-845.
84. Barbachyn M R, Hutchinson, Brickner S J, Cynamon M H, Kilburn J O, Klemens S P, Glickman S E, Grega K C, Hendges S K, Toops D S, Ford C W & Zurenko G E, Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity, J Med Chem, 39 (1996) 680-685.
85. Arima K, Imanaka H, Kousaka M, Fukuda A & Tamura G, Studies on pyrrolnitrin, a new antibiotic. I. Isolation and properties of pyrrolnitri, J Antibiot Ser A, 18 (1968) 201-204.
86. Bonde C G & Gaikwad N J, Synthesis and preliminary evaluation of some pyrazine containing thiazolines and thiazolidinones as antimicrobial agents, Bioorg Med Chem, 12 (2004) 2151-2161.
87. Waisser K, Gregor J, Kubicova L, Klimesova V, Kunes J, Machacek M & Kaustova J, New groups of antimycobacterial agents: 6-chloro-3-phenyl-4-thioxo-2H-1,3-benzoxazine-2(3H)-ones and 6-chloro-3-phenyl-2H-1,3-benzoxazine-2,4(3H)-dithiones, Eur J Med Chem, 35 (2000) 733-741.
88. Rodriguez A D, Ramirez C, Rodriguez II & Gonzalez E, Novel antimycobacterial benzoxazole alkaloids from the West Indian Sea whip Pseudopterogorgia elisabethae, Org Letts, 1 (1999) 527-530.
89. Mitscher L A & Baker W, Tuberculosis: A search for novel therapy starting with natural products, Med Res Rev, 18 (1997) 363-374.
90. Van Rensburg C E J, Joone G K, Sirgel F A, Matlola N M & O'Sullivan J F, In vitro Investigation of the Antimicrobial Activities of Novel Tetramethylpiperidine-Substituted Phenazines against Mycobacterium tuberculosis, Chemother, 46 (2000) 43-48.
91. McKee T C, Covington C D, Fuller R W, Bokesch H R, Young S, Cardellina II J H, Kadushin M R, Soejarto D D, Stevens P F, Cragg G M & Boyd M R, Pyranocoumarins from tropical species of the genus Calophyllum: A chemotaxonomic study of extracts in the National Cancer Institute collection, J Nat Prod, 61 (1998) 1252-1256.
92. Currens M J, Gulakowski R J, Mariner J M, Moran R A, Buckheit R W Jr., Gustafson K R, McMahon J B & Boyd M R, Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1, J Pharmacol Exp Therap, 279 (1996) 645-651.
93. Dharmaratne H R, Wanigasekera W M, Mata-Greenwood E & Pezzuto J M, Inhibition of human immunodeficiency virus type 1 reverse transcriptase activity by cordatolides isolated from Calophyllum cordato-oblongum, Planta Medica, 64 (1998) 460-461.
94. Spino C, Dodier M & Sotheeswaran S, Anti-HIV coumarins from Calophyllum seed oil, Biorg Med Chem Lett, 8 (1998) 3475-3478.
95. Xu Z Q, Lin Y M & Flavin M, Pat WO 200021514-A2.
96. Bruzzese T, Rimaroli C, Bonabello A, Mozzi G, Ajay S & Cooverj N D, Pharmacokinetics and tissue distribution of rifametane, a new 3-azinomethyl-rifamycin derivative, in several animal species, Arzneimittel-Forschung, 50 (2000) 60-71.
97. Strippoli V, Bruzzese T, Galli R & Siminetti N, The antibacterial activity of a new 3-azinomethylrifamycin. Il Farmaco Ed Sci, 43 (1988) 619-625.
98. Condos R, Rom W M & Schluger N W, Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol, Lancet, 349 (1997) 1513-1515.
99. Tramontana J M, Utaipat T, Molloy A, Akarasewi P, Burroughs M, Makonkawkeyoon S, Johnson B, Klausner J D, Rom W & Kaplan G, Thalidomide treatment reduces tumour necrosis factor production and enhances weight gain in patients with pulmonary tuberculosis. Molec Med, 1 (1995) 384-387.
100. Bishai W, Lipid lunch for persistent pathogen, Nature, 406 (2000) 683-685.
101. McKinney J D, Honer zu Bentrup K, Munoz Elias E J, Miczak A, Chen B, Chan W T, Swenson D, Sacchettini J C, Jacobs W R Jr & Russell D G, Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase, Nature, 406 (2000) 735-738.